Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

clinical trial

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT00051012

P6099clinical trial phasephase IV clinical trialQ42825046
P17countryCanadaQ16
United States of AmericaQ30
PolandQ36
SwitzerlandQ39
AustraliaQ408
GermanyQ183
AustriaQ40
United KingdomQ145
P582end time2006-10-01
P1050medical conditionlymphomaQ208414
mycosis fungoidesQ1891209
P2899minimum age18
P1132number of participants86
P6153research siteJewish General HospitalQ3145341
Southampton General HospitalQ7569131
University Hospital MuensterQ1748138
P580start time1995-09-01
P8363study typeinterventional studyQ78089383
P1476titleA Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25